Specialty R&D
Our Specialty portfolio delivers innovative medicines focused on meeting important medical needs across therapeutic categories, including neurology (Parkinson’s Disease, Migraine), endocrinology (Hypothyroidism), and other therapeutic areas.
We are focused on the continued growth and expansion of our product portfolio through internal development as well as through acquisitions and late-stage and next-generation product partnership opportunities.
Clinical Activities(1)
Product
Indication
Estimated Launch
IPX203
Parkinson’s Disease
Q3 2024(2)
DHE Autoinjector
Migraine and Cluster Headache
1H 2025
K-114
Hypothyroidism
2026-2027
Note: Data as of May 2024
(1) Pipeline includes investigational products not approved by FDA. Any such expected launch is subject to certain assumptions and factors, many of which are outside our control, such as regulatory approval, and may be subject to change.
(2) Pending successful CRL resolution and FDA approval.